Cargando…

SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot

Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1...

Descripción completa

Detalles Bibliográficos
Autores principales: Achtnichts, Lutz, Ovchinnikov, Arkady, Jakopp, Barbara, Oberle, Michael, Nedeltchev, Krassen, Fux, Christoph Andreas, Sellner, Johann, Findling, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/
https://www.ncbi.nlm.nih.gov/pubmed/35214799
http://dx.doi.org/10.3390/vaccines10020341
_version_ 1784658033853333504
author Achtnichts, Lutz
Ovchinnikov, Arkady
Jakopp, Barbara
Oberle, Michael
Nedeltchev, Krassen
Fux, Christoph Andreas
Sellner, Johann
Findling, Oliver
author_facet Achtnichts, Lutz
Ovchinnikov, Arkady
Jakopp, Barbara
Oberle, Michael
Nedeltchev, Krassen
Fux, Christoph Andreas
Sellner, Johann
Findling, Oliver
author_sort Achtnichts, Lutz
collection PubMed
description Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme.
format Online
Article
Text
id pubmed-8875864
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-88758642022-02-26 SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot Achtnichts, Lutz Ovchinnikov, Arkady Jakopp, Barbara Oberle, Michael Nedeltchev, Krassen Fux, Christoph Andreas Sellner, Johann Findling, Oliver Vaccines (Basel) Article Evidence suggests limited development of protective IgG responses to mRNA-based vaccines in sphingosine-1-phosphate receptor (S1PR)-modulator treated individuals with multiple sclerosis (MS). We studied the extent of the humoral immune response after the preferred third mRNA SARS-CoV-2 vaccine in S1PR-modulator treated people with MS (pwMS) and insufficient IgG responses after the standard immunization scheme. Eight pwMS that were treated with fingolimod received a third homologous SARS-CoV-2 mRNA vaccine dose, either the Moderna’s mRNA-1273 or Pfizer-BioNTech’s BNT162b2 vaccine. We quantified the serum levels of IgG antibodies against the receptor-binding domain of SARS-CoV-2 four weeks later. An antibody titer of 100 AU/mL or more was considered protective. After the third vaccination, we found clinically relevant IgG titers in four out of eight individuals (50%). We conclude that the humoral immune response may reach protective levels after the third preferred dose of the homologous SARS-CoV-2 mRNA vaccine. Vaccine shots in S1PR-modulator treated pwMS ahead of schedule may be a strategy to overcome insufficient humoral immune responses following the standard vaccination scheme. MDPI 2022-02-21 /pmc/articles/PMC8875864/ /pubmed/35214799 http://dx.doi.org/10.3390/vaccines10020341 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Achtnichts, Lutz
Ovchinnikov, Arkady
Jakopp, Barbara
Oberle, Michael
Nedeltchev, Krassen
Fux, Christoph Andreas
Sellner, Johann
Findling, Oliver
SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title_full SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title_fullStr SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title_full_unstemmed SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title_short SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot
title_sort sars-cov-2 mrna vaccination in people with multiple sclerosis treated with fingolimod: protective humoral immune responses may develop after the preferred third shot
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875864/
https://www.ncbi.nlm.nih.gov/pubmed/35214799
http://dx.doi.org/10.3390/vaccines10020341
work_keys_str_mv AT achtnichtslutz sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT ovchinnikovarkady sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT jakoppbarbara sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT oberlemichael sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT nedeltchevkrassen sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT fuxchristophandreas sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT sellnerjohann sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot
AT findlingoliver sarscov2mrnavaccinationinpeoplewithmultiplesclerosistreatedwithfingolimodprotectivehumoralimmuneresponsesmaydevelopafterthepreferredthirdshot